Campora E, Vidili G, Oliva C, Ardizzoni A, Rosso R
Department of Medical Oncology, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
Oncology. 1991;48(5):403-5. doi: 10.1159/000226969.
Twenty-four patients with severe post-chemotherapy emesis (greater than 15 emetic episodes) refractory to prior combination antiemetic therapy were treated with a selective 5-HT3 receptor antagonist ondansetron (GR38032F). Ondansetron was given as 8 mg three times daily orally for 5 days with the first dose given 1 h prior to chemotherapy. Control of emesis was evaluated over the 5-day period. All chemotherapy was administered on an outpatient basis. Worst day analysis of antiemetic response was 87.5%: complete protection in 9/24 patients (37.5%) and major protection (1-2 emetic episodes) in 12/24 patients (50%). No protection from emesis was observed in 3 patients (12.5%). No side effects and no alterations in liver function tests were observed. Ondansetron is a safe and highly effective antiemetic agent.
24例化疗后严重呕吐（呕吐发作超过15次）且对先前联合止吐治疗无效的患者，接受了选择性5-羟色胺3（5-HT3）受体拮抗剂昂丹司琼（GR38032F）治疗。昂丹司琼的给药方式为每日3次，每次8mg，口服，共5天，首剂在化疗前1小时服用。在5天的时间里评估呕吐的控制情况。所有化疗均在门诊进行。止吐反应的最差日分析显示，有效率为87.5%：9/24例患者（37.5%）完全得到保护，12/24例患者（50%）得到主要保护（呕吐发作1 - 2次）。3例患者（12.5%）未得到呕吐保护。未观察到副作用，肝功能检查也无变化。昂丹司琼是一种安全且高效的止吐药。
